The significant investigation into the design of PRMT5 and MAT2A inhibitors in recent years makes the possibility of co-inhibition of MTAP a new possibility for MTAP+/+cancers as well as its use as a monotherapy46,47. This evidence concerns the gene MAT2A and cancer.